{
  "docId": "019de073-b144-743c-94c4-bc5a80eb44df",
  "docSlug": "9540d42c57dd536e8cb82c97bd211004",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 50 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 10,
  "pageCount": 50,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Slide highlights clinical development status and key value propositions for two lead assets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-b144-743c-94c4-bc5a80eb44df/10",
  "deckHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df",
  "deckJsonHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df.json",
  "deckAnchorHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.68,
        "y": 0.55
      },
      "kind": "callout",
      "text": "Potential first-in-category treatment for female sexual arousal disorder (FSAD). Topical cream, same active ingredient as Viagra®",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c3a6d21-2e3f-408a-8648-0c06dee7159f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.68,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Potential first-in-category hormone-free contraception. Self-administered intravaginal drug/device",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1122e29-d4ef-4839-bbdf-d51f3591ae1f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.08,
        "x": 0.33,
        "y": 0.26
      },
      "kind": "image",
      "text": "Bayer and NIH logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18d6fb4a-256e-47c8-92e8-3dc4ab453b1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Investigational hormone-free, monthly intravaginal contraceptive. Designed to be an easy-to-use monthly option. Commercial license agreement with Bayer.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f42f16d-2f5b-4286-b591-af39b9b0e579",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "Investigational cream formulation of sildenafil. FSAD is a physiological condition. No FDA-approved treatments.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "203a0032-6fc1-4715-a707-8a4345c6439b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Ovaprene®: Hormone-Free, Monthly Contraception. Pivotal Phase 3 Study to Commence 2023*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03fac2ac-9aa9-4e5a-8b21-690e3dbdad9f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Sildenafil Cream, 3.6%^: Female Sexual Arousal Disorder. Phase 2b Study Enrollment to Complete 4Q-2022*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9050705e-ae24-4268-b3b1-586fe701a246",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.15,
        "y": 0.05
      },
      "kind": "title",
      "text": "Advancing Products Women Want – Late Stage Programs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bea29cfb-1830-41a9-99f3-e313ff706830",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}